| http://purl.uniprot.org/citations/15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/15247625 | http://www.w3.org/2000/01/rdf-schema#comment | "ObjectiveAbacavir, a human immunodeficiency virus-1 (HIV-1) nucleoside-analogue reverse transcriptase inhibitor, causes severe hypersensitivity in 4-8% of patients. HLA B*5701 is a known genetic risk factor for abacavir hypersensitivity in Caucasians. Our aim was to confirm the presence of this genetic factor in our patients, and to determine whether genotyping for HLA B*5701 would be a cost-effective use of healthcare resources.MethodsPatients with and without abacavir hypersensitivity were identified from a UK HIV clinic. Patients were genotyped for HLA B*5701, and pooled data used for calculation of test characteristics. The cost-effectiveness analysis incorporated the cost of testing, cost of treating abacavir hypersensitivity, and the cost and selection of alternative antiretroviral regimens. A probabilistic decision analytic model (comparing testing versus no testing) was formulated and Monte Carlo simulations performed.ResultsOf the abacavir hypersensitive patients, six (46%) were HLA B*5701 positive, compared to five (10%) of the non-hypersensitive patients (odds ratio 7.9 [95% confidence intervals 1.5-41.4], P = 0.006). Pooling of our data on HLA B*5701 with published data resulted in a pooled odds ratio of 29 (95% CI 6.4-132.3; P < 0.0001). The cost-effectiveness model demonstrated that depending on the choice of comparator, routine testing for HLA B*5701 ranged from being a dominant strategy (less expensive and more beneficial than not testing) to an incremental cost-effectiveness ratio (versus no testing) of Euro 22,811 per hypersensitivity reaction avoided.ConclusionsAbacavir hypersensitivity is associated with HLA B*5701, and pre-prescription pharmacogenetic testing for this appears to be a cost-effective use of healthcare resources."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.org/dc/terms/identifier | "doi:10.1097/00008571-200406000-00002"xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/author | "Hughes D.A."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/author | "Pirmohamed M."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/author | "Park B.K."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/author | "Alfirevic A."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/author | "Ward C.C."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/author | "Vilar F.J."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/date | "2004"xsd:gYear |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/name | "Pharmacogenetics"xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/pages | "335-342"xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/title | "Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity."xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://purl.uniprot.org/core/volume | "14"xsd:string |
| http://purl.uniprot.org/citations/15247625 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/15247625 |
| http://purl.uniprot.org/citations/15247625 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A0A7C552-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A0E3DC98-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A0E3DCA0-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A0E3DCA1-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A068B107-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A068B112-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A068B116-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A068B2J5-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |
| http://purl.uniprot.org/uniprot/#_A0A068B2Z1-mappedCitation-15247625 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/15247625 |